Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development.
The company was established in 2007 and currently employs 450 professionals. It is headquartered in Krakow, Poland, and foreign offices located in Boston, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK.
Since its incorporation in 2007 it has provided efficient and effective drug discovery support for pharma and biotech companies’ programmes based on broad capabilities and thorough experience in small molecule drug discovery, starting from target validation up to the selection of a clinical candidate. Its laboratories are both GLP- and GMP-certified.
Selvita scientific team aims at building strong partnerships and becoming an integral part of clients’ organizations ensuring out-of-the box thinking, strong IP protection and goal achievement.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner